Mind Medicine (MindMed) Inc. (MNMD) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Vancouver, BC, カナダ. 現CEOは Robert Barrow.
MNMD を有する IPO日 2016-11-15, 74 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $1.56B.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
